Ignite Creation Date:
2025-12-24 @ 7:51 PM
Ignite Modification Date:
2026-01-28 @ 9:51 PM
Study NCT ID:
NCT02934204
Status:
UNKNOWN
Last Update Posted:
2016-10-14
First Post:
2016-10-13
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma
Sponsor:
Guangdong Provincial People's Hospital
Organization:
Study Overview
Official Title:
Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma
Status:
UNKNOWN
Status Verified Date:
2016-05
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Consolidation treatment for Primary Central Nervous System Diffuse Large B cell Lymphoma(PCNSL)patients remains to be defined.Here we designed a tolerated treatment of HDMTX plus Temozolomide,followed by consolidation with Temozolomide in PCNSL patients.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: